Journals / İstanbul Medical Journal / 2015 / Cilt: 16 - Sayı: 3

Aggressive Natural Killer Cell Leukemia: A Case Report and Literature Update

Agresif Naturel Killer Hücreli Lösemi: Olgu Sunumu ve Literatür güncellemesi

Pages
130–132
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Here, we report a rare case of a patient diagnosed with ANKL.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aggressive natural killer cell leukemia (ANKL) is an extremely rare type of leukemia characterized by clonal NK cell infiltration of peripheral blood and the bone marrow, cytopenias, and hepato/splenomegaly.
📊
Key Findings & Data:Immunological studies determine CD3-/CD16+/CD56+ and cytoplasmic CD3+.
💡
Conclusion & Impact:Here, we report a rare case of a patient diagnosed with ANKL.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aggressive natural killer cell leukemia (ANKL) is an extremely rare type of leukemia characterized by clonal NK cell infiltration of peripheral blood and the bone marrow, cytopenias, and hepato/splenomegaly. ANKL is an ag- gressive subtype of a large granular lymphocytic (LGL) leukemia. Peripheral blood smear shows LGL cells containing characteristic azurophilic granules in a light pale basophilic cytoplasm and immature nuclei. Immunological studies determine CD3-/CD16+/CD56+ and cytoplasmic CD3+. Tumor cells may have EBV positive. Chemotherapy resistance is caused by a multi-drug resistance gene (MDR); thus, patients die within 2 months after diagnosis. Here, we report a rare case of a patient diagnosed with ANKL.

Özet

Agresif Naturel Killer hücreli Lösemi (ANKL), periferik kan ve kemik iliğinde klonal naturel killer (NK) hücre infiltrasyonu, sitopeniler ve hepato/splenomegali ile karakterize çok nadir rastlanan bir lösemi tipidir. Large Granüler Lenfositik (LGL) lösemilerin agresif seyirli bir alt tipidir. Periferik yaymada karakteristik olarak; hafif soluk ve bazofilik sitoplazmada büyük azurofilik granülleri içeren nükleusları immatür LGL hücreleri dikkati çeker. İmmünolojik çalışmada CD3-/CD16+/CD56+ ve sitoplazmik CD3+ saptanır. Tümör hücreleri EBV pozitif olabilir. MDR gen sebebi ile kemoterapiye dirençli olup, hastalar genel olarak tanıdan sonra iki ay içinde kaybedilirler. Burada ANKL tanısı koyduğumuz olgumuzu çok nadir rastlanması sebebi ile sunduk.

🔖

Cite This Article

UĞURLUOĞLU, C., SAKİN, A., BAŞTÜRK, A., ANDIÇ, N., KUTLU, O., ECİRLİ, Ş. (2022). Aggressive Natural Killer Cell Leukemia: A Case Report and Literature Update. İstanbul Medical Journal, Cilt: 16 - Sayı: 3, 130–132. https://ajindex.com/articles/552161

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Lim MS, de Leval L, Quintanilla- Martinez L. Commentary on the 2008 WHO classification of mature T and NK neoplasms. J Hematop 2009; 2: 65-73. [CrossRef] Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood 1993; 82: 1-14.
  2. İmamura N, Kimura A. Neutropenia among survivors of atomic bomb explosion. Lancet 2000; 355: 117. [CrossRef] Gelb AB, van de Rijn M, Regula DP Jr, Combleet JP, Kamei OW, Horou- pian DS, et al. Epstein-Barr virus associated natural killer- large granu- lar lymphocyte leukemia. Hum Pathol 1994; 25: 953-60. [CrossRef] Morice WG, Kurtin PJ, Leibson PJ, Tefferi A, Hanson CA, et al. Demon- stration of aberrant T-cell and natural killer-cell antigen expression in all cases of granular lymphocytic leukemia. Br J Haematol 2003; 120: 1026-36. [CrossRef] Suzuki R, Suzumiya J, Nakamura S. Aggressive natural killer-cell leu- kemia revisited: Large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia 2004; 18: 763-70. [CrossRef] Takami A, Nakao S, Yachie A, Kasahara Y, Okumura H, Miura Y. Suc- cessful treatement of Epstein Barr virus - associated natural killer cell large granular lymphocytic leukemia using allogenic peripheral blood stem cell transplantation. Bone Marrow Transplant 1998; 21: 1279-82. [CrossRef]